Sygnature Discovery Partners with Insmed to develop first-in-class compounds for genetically defined diseases

Sygnature Discovery has been selected by Insmed Innovation UK, the Cambridge-based subsidiary of Insmed Incorporated, a global biopharmaceutical company headquartered in New Jersey, USA, to partner on an integrated drug discovery collaboration.

Insmed will draw on Sygnature Discovery’s considerable expertise in bringing together scientific disciplines to deliver compounds against novel biological targets for genetically defined diseases.

These novel targets are the basis for several programmes initiated by Insmed that aim to deliver first-in-class therapeutics to patient populations with severe unmet medical needs.


Stuart Onions, Senior Vice-President, Alliance Management at Sygnature Discovery, said:

“Sygnature and Insmed are truly complementary teams. We work seamlessly together allowing each party to focus on what they know best: compelling new areas of biology, target discovery and validation in the case of Insmed, and multi-disciplinary, multi-modality drug design and development in ours.

“The Sygnature team are truly excited by the collaboration – our second with this team.”


Tom Heightman, SVP Research at Insmed, also commented:

“Having worked successfully with Sygnature in the past and knowing their team of experienced scientists, track record, and infrastructure, it was a pleasure to select Sygnature as a strategic partner.

“Sygnature’s co-located scientific operations allow for rapid design-make-test cycles across all services, including protein crystallography, biophysics, and medicinal chemistry.  We look forward to making rapid progress on the novel targets we are working on together.”


About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation based in the UK and Canada with its headquarters in Nottingham and additional sites in Alderley Park, Macclesfield, Glasgow, Montreal and Quebec City. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations. Since 2004, Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.